Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT06058156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy. Participants will be randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo. Participants who meet inclusion/exclusion criteria will be stratified for randomization by severity of AD (moderate \[baseline EASI score \<22\] versus severe \[baseline EASI score ≥22\]). The total duration of study is approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for double-blind study treatment and 4 weeks for follow-up.
Study identification
- NCT ID
- NCT06058156
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2023
- Primary completion
- Oct 22, 2025
- Completion
- Nov 19, 2025
- Last update posted
- Dec 10, 2025
2023 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clear Dermatology & Aesthetics Center- Site Number : 8400003 | Scottsdale | Arizona | 85255 | — |
| Encore Medical Research of Boynton Beach- Site Number : 8400002 | Boynton Beach | Florida | 33436 | — |
| Revival Research - Doral- Site Number : 8400007 | Doral | Florida | 33122 | — |
| Encore Medical Research - 6600 Taft St- Site Number : 8400004 | Hollywood | Florida | 33024 | — |
| Sullivan Dermatology- Site Number : 8400001 | Miami | Florida | 33162 | — |
| ARA Professionals- Site Number : 8400017 | Miami | Florida | 33176-1032 | — |
| Encore Medical Research - Weston- Site Number : 8400008 | Weston | Florida | 33331 | — |
| Wayne Health - Dearborn- Site Number : 8400009 | Dearborn | Michigan | 48126 | — |
| UPMC Montefiore- Site Number : 8400006 | Pittsburgh | Pennsylvania | 15213 | — |
| ACRC Trials - Carrollton - Hunt - PPDS- Site Number : 8400012 | Carrollton | Texas | 75010-4632 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06058156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06058156 live on ClinicalTrials.gov.